Evidence map›Paper›PMID 31885628›Full record

ArticleStem cells international2019

MicroRNA-28-5p Regulates Liver Cancer Stem Cell Expansion via IGF-1 Pathway.

Qing Xia, Tao Han, Pinghua Yang, Ruoyu Wang, Hengyu Li, Jin Zhang, Xinfeng Zhou

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Cancer Stem Cells from Definition to Detection and Targeted Drugs.International journal of molecular sciences · 2024
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Recent progress in treatment of hepatocellular carcinoma.American journal of cancer research · 2020
    Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Qing Xia *Department of General Surgery, Hua Mei Hospital, University of Chinese Academy of Sciences, Ningbo, China.
Tao Han *Department of Oncology, General Hospital of Northern Theater Command, Shenyang, Liaoning Province, China.
Pinghua Yang *Department of General Surgery, Third Affiliated Hospital of Second Military Medical University, Shanghai, China.
Ruoyu Wang *Department of General Surgery, Third Affiliated Hospital of Second Military Medical University, Shanghai, China.
Hengyu LiDepartment of General Surgery, First Affiliated Hospital of Second Military Medical University, Shanghai, China.ORCID https://orcid.org/0000-0002-1007-6493
Jin ZhangDepartment of General Surgery, Third Affiliated Hospital of Second Military Medical University, Shanghai, China.ORCID https://orcid.org/0000-0002-0874-5379
Xinfeng ZhouDepartment of General Surgery, Hua Mei Hospital, University of Chinese Academy of Sciences, Ningbo, China.ORCID https://orcid.org/0000-0001-7597-8458
Second Military Medical University · CNUniversity of Chinese Academy of Sciences · CNGeneral Hospital of Shenyang Military Region · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMicroRNAs (miRNAs) play a critical role in the regulation of cancer stem cells (CSCs). However, the role of miRNAs in liver CSCs has not been fully elucidated.

methodsReal-time PCR was used to detect the expression of miR-miR-28-5p in liver cancer stem cells (CSCs). The impact of miR-28-5p on liver CSC expansion was investigated both in vivo and in vitro. The correlation between miR-28-5p expression and sorafenib benefits in HCC was further evaluated in patient-derived xenografts (PDXs).

resultsOur data showed that miR-28-5p was downregulated in sorted EpCAM- and CD24-positive liver CSCs. Biofunctional investigations revealed that knockdown miR-28-5p promoted liver CSC self-renewal and tumorigenesis. Consistently, miR-28-5p overexpression inhibited liver CSC's self-renewal and tumorigenesis. Mechanistically, we found that insulin-like growth factor-1 (IGF-1) was a direct target of miR-28-5p in liver CSCs, and the effects of miR-28-5p on liver CSC's self-renewal and tumorigenesis were dependent on IGF-1. The correlation between miR-28-5p and IGF-1 was confirmed in human HCC tissues. Furthermore, the miR-28-5p knockdown HCC cells were more sensitive to sorafenib treatment. Analysis of patient-derived xenografts (PDXs) further demonstrated that the miR-28-5p may predict sorafenib benefits in HCC patients.

conclusionOur findings revealed the crucial role of the miR-28-5p in liver CSC expansion and sorafenib response, rendering miR-28-5p an optimal therapeutic target for HCC.

Identifiers

PMID31885628
PMCPMC6915025
OpenAlexW2991675950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.